X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AMAR REMEDIES with BATA INDIA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AMAR REMEDIES vs BATA INDIA - Comparison Results

BATA INDIA 
   Change

Bata is India's largest footwear retailer of India. It is a part of the Bata Shoe Organisation and was incorporated in the year 1931. The company also manufactures footwear and has a wide retail network of over 1200 stores across India. It sells over... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AMAR REMEDIES BATA INDIA AMAR REMEDIES/
BATA INDIA
 
P/E (TTM) x -0.5 49.9 - View Chart
P/BV x 0.1 9.2 0.7% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 AMAR REMEDIES   BATA INDIA
EQUITY SHARE DATA
    AMAR REMEDIES
Jun-12
BATA INDIA
Mar-17
AMAR REMEDIES/
BATA INDIA
5-Yr Chart
Click to enlarge
High Rs164614 26.7%   
Low Rs86400 21.5%   
Sales per share (Unadj.) Rs261.6192.5 135.9%  
Earnings per share (Unadj.) Rs17.412.4 140.6%  
Cash flow per share (Unadj.) Rs22.317.4 127.9%  
Dividends per share (Unadj.) Rs03.50 0.0%  
Dividend yield (eoy) %00.7 0.0%  
Book value per share (Unadj.) Rs100.7103.0 97.8%  
Shares outstanding (eoy) m26.16128.53 20.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.52.6 18.1%   
Avg P/E ratio x7.241.0 17.5%  
P/CF ratio (eoy) x5.629.1 19.3%  
Price / Book Value ratio x1.24.9 25.2%  
Dividend payout %028.3 0.0%   
Avg Mkt Cap Rs m3,27065,139 5.0%   
No. of employees `000NA4.7 0.0%   
Total wages/salary Rs m1632,732 6.0%   
Avg. sales/employee Rs ThNM5,300.5-  
Avg. wages/employee Rs ThNM585.2-  
Avg. net profit/employee Rs ThNM340.5-  
INCOME DATA
Net Sales Rs m6,84424,743 27.7%  
Other income Rs m21460 4.6%   
Total revenues Rs m6,86525,203 27.2%   
Gross profit Rs m1,1312,786 40.6%  
Depreciation Rs m128650 19.7%   
Interest Rs m39840 987.6%   
Profit before tax Rs m6262,555 24.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-50-217 23.1%   
Tax Rs m121749 16.2%   
Profit after tax Rs m4551,589 28.6%  
Gross profit margin %16.511.3 146.8%  
Effective tax rate %19.329.3 65.9%   
Net profit margin %6.66.4 103.5%  
BALANCE SHEET DATA
Current assets Rs m4,90413,619 36.0%   
Current liabilities Rs m3,5814,948 72.4%   
Net working cap to sales %19.335.0 55.2%  
Current ratio x1.42.8 49.8%  
Inventory Days Days124105 118.0%  
Debtors Days Days10010 978.2%  
Net fixed assets Rs m1,6892,908 58.1%   
Share capital Rs m262643 40.8%   
"Free" reserves Rs m2,35812,601 18.7%   
Net worth Rs m2,63513,243 19.9%   
Long term debt Rs m5070-   
Total assets Rs m6,86219,231 35.7%  
Interest coverage x2.664.4 4.0%   
Debt to equity ratio x0.20-  
Sales to assets ratio x1.01.3 77.5%   
Return on assets %12.48.5 146.7%  
Return on equity %17.312.0 143.9%  
Return on capital %31.018.0 172.6%  
Exports to sales %4.00-   
Imports to sales %00-   
Exports (fob) Rs m273NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m273365 74.7%   
Fx outflow Rs m22,035 0.1%   
Net fx Rs m271-1,669 -16.2%   
CASH FLOW
From Operations Rs m-3132,565 -12.2%  
From Investments Rs m-489-2,288 21.3%  
From Financial Activity Rs m769-557 -138.0%  
Net Cashflow Rs m-33-280 11.6%  

Share Holding

Indian Promoters % 25.5 0.0 -  
Foreign collaborators % 0.0 53.0 -  
Indian inst/Mut Fund % 9.2 9.8 93.9%  
FIIs % 0.0 20.1 -  
ADR/GDR % 0.0 0.0 -  
Free float % 65.3 17.1 381.9%  
Shareholders   13,061 83,621 15.6%  
Pledged promoter(s) holding % 99.7 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AMAR REMEDIES With:   COLGATE  HIND. UNILEVER  BAJAJ CORP  K.S.OILS LTD  P&G HYGIENE  

Compare AMAR REMEDIES With:   UNILEVER PLC. (UK)  P&G (US)  HYPERMARCAS (Brazil)  



Today's Market

Sensex Opens Lower; Realty & Auto Stocks Top Losers(09:30 am)

Asian shares eased in holiday-thinned trading on Monday and the safe haven yen gained as China canceled upcoming tariff talks with the United States.

Related Views on News

BATA INDIA Announces Quarterly Results (1QFY19); Net Profit Up 36.6% (Quarterly Result Update)

Jul 25, 2018 | Updated on Jul 25, 2018

For the quarter ended June 2018, BATA INDIA has posted a net profit of Rs 826 m (up 36.6% YoY). Sales on the other hand came in at Rs 8 bn (up 7.3% YoY). Read on for a complete analysis of BATA INDIA's quarterly results.

BATA INDIA Announces Quarterly Results (4QFY18); Net Profit Up 44.9% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, BATA INDIA has posted a net profit of Rs 521 m (up 44.9% YoY). Sales on the other hand came in at Rs 6 bn (up 5.7% YoY). Read on for a complete analysis of BATA INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AMAR REMEDIES SHARE PRICE


Dec 11, 2013 (Close)

TRACK AMAR REMEDIES

  • Track your investment in AMAR REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AMAR REMEDIES 8-QTR ANALYSIS

COMPARE AMAR REMEDIES WITH

MARKET STATS